Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
NCT ID: NCT01070186
Last Updated: 2012-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
See intervention descriptions
Sunitinib
50mg/day for 4 weeks
Tumor biopsy
Conducted prior to administration of sunitinib therapy
Nephrectomy
Nephrectomy 2-4 weeks after last dose of Sunitinib
Biomarkers
Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.
Biomarker evaluation of tissue prior to 4 week administration of Sunitinib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sunitinib
50mg/day for 4 weeks
Tumor biopsy
Conducted prior to administration of sunitinib therapy
Nephrectomy
Nephrectomy 2-4 weeks after last dose of Sunitinib
Biomarkers
Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.
Biomarker evaluation of tissue prior to 4 week administration of Sunitinib
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be eligible to undergo a radical or partial nephrectomy
* Clinical stage T1b, T2, T3, T4 and/or N1 disease as documented by abdomen/pelvis CT scan, or MRI and chest x-ray or CT chest
* Patients must have a performance status on the ECOG scale of 0-1
* Patients must have a pretreatment wbc \> 3.0, granulocyte count \> 1000/mm3, hemoglobin \> 8.5 g/dL, platelet count \> 100,000/mm3 and a normal PT and PTT
* Patients must have a serum creatinine \< 2.0 mg/dL
* Patients must have adequate hepatic function with a serum bilirubin \< upper limit of normal and AST/ALT \< 2.5 x upper limit of normal
Exclusion Criteria
* Prior administration of immunotherapy/biotherapy/hormonal or radiation for renal cell carcinoma
* Active secondary malignancies (other than basal cell carcinoma of the skin)
* Serious, nonhealing wound, ulcer, or bone fracture
* Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication or Grade II or greater peripheral vascular disease within 1 year preceding Day 0
* Any history or radiologic evidence of central nervous system disease
* Active infection requiring parenteral antibiotics at the time of the first Sunitinib administration
* Current or recent (within the 10 days preceding Day 0) use of oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanency indwelling IV catheters), or aspirin
* Current, recent (within the 4 weeks preceding Day 0), or planned participation in another experimental drug study
* Screening clinical laboratory values:
* ANC of \< 1000/uL
* Platelet count of \< 100,000/uL
* Total bilirubin \> 2.0 mg/dL
* AST or ALT \> 2.5 times the upper limit of normal
* Serum creatinine of \> 2.0 mg/dL
* Hemoglobin of \< 9 gm/dL (may be transfused to maintain or exceed this level)
* Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade \> 2
* Prolonged QTc interval on baseline EKG
* Uncontrolled hypertension (\>150/100 mm Hg despite optimal medical therapy)
* Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
* Patients receiving CYP3A4 inducers or inhibitors; patients should not take grapefruit juice or St. John's Wort while on the study
* History of psychiatric disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
* Unable to take medication by mouth
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UCLA Jonsson Comprehensive Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fairooz Kabbinavar, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-07-068
Identifier Type: -
Identifier Source: org_study_id